… Therefore, based on these results, we can observe a promising role of BCG in cancer. BCG
induces type I IFN and results in signaling and APC activation. This inflammatory axis could …

… receiving adequate bacillus Calmette-Guérin therapy at a tertiary cancer center between …
-free survival—muscle-invasive bladder cancer and overall survival were used to create …

Background Whether the commonly used bacillus Calmette-Guérin (BCG) strains Connaught
and Tice confer different treatment responses in non–muscle-invasive bladder cancer (…

… Bacillus Calmette-Guérin (BCG) immunotherapy to prevent the recurrence and progression
… strains are undergoing clinical trial testing to improve outcomes for bladder cancer patients. …

… Our consensus provides a precise definition of the disease state for bladder cancer not
invading the bladder muscle and exposed to bacillus Calmette-Guérin (BCG) treatment. Clear …

… of nephron-sparing therapy, bacillus Calmette–Guérin (BCG) … Here, we compared oncological
outcomes and safety … in terms of toxicity and oncological outcomes. Our result showed that …

… We determine if intravesical bacillus Calmette-Guerin (BCG) reduces the risk of progression
after … or higher in patients with superficial (stage Ta, T1 or carcinoma in situ) bladder cancer. …

… After more than 30 yr of research, bacillus Calmette-Guérin (BCG) remains the most effective
intravesical treatment in non–muscle-invasive bladder cancer (NMIBC). The key element of …

… cancer is controversial. We investigated if induction therapy with low dose bacillus Calmette-…
to that of standard dose bacillus Calmette-Guérin, with less toxicity and higher quality of life. …

… invasive bladder cancer after previous intravesical bacillus Calmette-Guérin. Bacillus Calmette-…
failed 1 or more courses of prior bacillus Calmette-Guérin therapy were included. Studies …